ArticleHepatology (Baltimore, Md.)2014
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response.
Article in Hepatology (Baltimore, Md.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review.PharmacoEconomics · 2020Pooled it
- Trial
- Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results.World journal of virology · 2017Article
- Hepatitis C virus double-stranded RNA is the predominant form in human liver and in interferon-treated cells.Hepatology (Baltimore, Md.) · 2017Article
- CD56Journal of leukocyte biology · 2017Article
- Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis.ClinicoEconomics and outcomes research : CEOR · 2017Article
- Efficacy and direct costs of chronic hepatitis C treatment with first generation NS3/4A protease inhibitors in a real life population.Clinical and experimental hepatology · 2016Article
- Real-World Drug Costs of Treating Hepatitis C Genotypes 1-4 with Direct-Acting Antivirals: Initiating Treatment at Fibrosis 0-2 and 3-4.Journal of managed care & specialty pharmacy · 2016Article
- Review
- How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study.BMC health services research · 2016Article
- Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.PLoS medicine · 2016Article
- A new paradigm evaluating cost per cure of HCV infection in the UK.Hepatology, medicine and policy · 2016Article
- Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study.PloS one · 2016Article
- Drug Pricing Evolution in Hepatitis C.PloS one · 2016Article
- Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV).Advances in therapy · 2015Article
- Hepatitis C virus: Virology, diagnosis and treatment.World journal of hepatology · 2015Review
- Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective.International journal of hepatology · 2015Review
- Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C.PloS one · 2015Article
- Primary Care-Based Hepatitis C Treatment Outcomes With First-Generation Direct-Acting Agents.Journal of addiction medicineObservational
- The hepatitis C genotype 1 paradox: cost per treatment is increasing, but cost per cure is decreasing.Canadian journal of gastroenterology & hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 1 institution in 1 country.
Funding
Abstract
unlabelledIn registration trials, triple therapy with telaprevir (TVR), pegylated interferon (Peg-IFN), and ribavirin (RBV) achieved sustained virological response (SVR) rates between 64% and 75%, but the clinical effectiveness and economic burdens of this treatment in real-world practice remain to be determined. Records of 147 patients who initiated TVR-based triple therapy at the Mount Sinai Medical Center (May-December 2011) were reviewed. Direct medical costs for pretreatment, on-treatment, and posttreatment care were calculated using data from Medicare reimbursement databases, RED Book, and the Healthcare Cost and Utilization Project database. Costs are presented in 2012 U.S. dollars. SVR (undetectable hepatitis C virus [HCV] RNA 24 weeks after the end of treatment) was determined on an intention-to-treat basis. Cost per SVR was calculated by dividing the median cost by the SVR rate. Median age of the 147 patients was 56 years (interquartile range [IQR] = 51-61), 68% were male, 19% were black, 11% had human immunodeficiency virus/HCV coinfection, 36% had advanced fibrosis/cirrhosis (FIB-4 scores ≥3.25), and 44% achieved an SVR. The total cost of care was $11.56 million. Median cost of care was $83,721 per patient (IQR = $66,652-$98,102). The median cost per SVR was $189,338 (IQR = $150,735-$221,860). Total costs were TVR (61%), IFN (24%), RBV (4%), adverse event management (8%), professional fees (2%), and laboratory tests (1%).
conclusionsTVR and Peg-IFN accounted for 85% of costs. Pharmaceutical prices and the low (44%) SVR rate, in this real-world study, were major contributors to the high cost per SVR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.